moonlightbae
2021-10-29
Poggers HODL forever 😎
AbbVie got a shot in the arm from newer drug sales and lifted profit view<blockquote>艾伯维从新药销售中得到了一剂强心针，利润前景也得到了提升</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":857350894,"tweetId":"857350894","gmtCreate":1635510411515,"gmtModify":1635510412811,"author":{"id":3575016656391852,"idStr":"3575016656391852","authorId":3575016656391852,"authorIdStr":"3575016656391852","name":"moonlightbae","avatar":"https://static.tigerbbs.com/9e8bead30ce122327046cb50ca725a77","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":72,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Poggers HODL forever 😎</p></body></html>","htmlText":"<html><head></head><body><p>Poggers HODL forever 😎</p></body></html>","text":"Poggers HODL forever 😎","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/857350894","repostId":1140565656,"repostType":4,"repost":{"id":"1140565656","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635508153,"share":"https://www.laohu8.com/m/news/1140565656?lang=zh_CN&edition=full","pubTime":"2021-10-29 19:49","market":"us","language":"en","title":"AbbVie got a shot in the arm from newer drug sales and lifted profit view<blockquote>艾伯维从新药销售中得到了一剂强心针，利润前景也得到了提升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1140565656","media":"Tiger Newspress","summary":"U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third ti","content":"<p>U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.</p><p><blockquote>美国制药商艾伯维公司 (ABBV.N) 周五第三次上调了 2021 年调整后利润预期，此前其新药的出色表现帮助其季度收入超出了华尔街的预期。</blockquote></p><p> The company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition for its blockbuster rheumatoid arthritis drug, Humira.</p><p><blockquote>该公司一直专注于获得更多批准并推动 2019 年推出的 Skyrizi 和 Rinvoq 的增长，为其重磅类风湿性关节炎药物 Humira 的竞争做准备。</blockquote></p><p> Humira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. The company's newer drugs, Skyrizi and Rinvoq, are approved to treat the same conditions as Humira.</p><p><blockquote>修美乐是全球销量最高的药品，占艾伯维总销售额的近40%。该公司的新药Skyrizi和Rinvoq被批准用于治疗与Humira相同的病症。</blockquote></p><p> Humira sales, which rose 5.6% to $5.43 billion in the third quarter, are expected to be squeezed when generic rivals enter the U.S. market in 2023.</p><p><blockquote>修美乐第三季度销售额增长 5.6%，达到 54.3 亿美元，预计当仿制药竞争对手于 2023 年进入美国市场时，销售额将受到挤压。</blockquote></p><p> Rinvoq sales could take a near-term hit, analysts have said, after the U.S. drug regulator asked the company and others to present information about the risks of death and serious conditions from the use of their drugs that belong to a class of treatments known as JAK inhibitors.</p><p><blockquote>分析师表示，Rinvoq 的销售可能会在短期内受到打击，此前美国药品监管机构要求该公司和其他公司提供有关使用属于一类被称为 JAK 抑制剂的药物造成的死亡和严重疾病的风险的信息。</blockquote></p><p> Meanwhile, Rinvoq sales more than doubled to $453 million in the quarter ended Sept. 30, beating the average analyst estimate of $436.8 million, according to Refinitiv IBES estimates.</p><p><blockquote>与此同时，根据 Refinitiv IBES 的估计，截至 9 月 30 日的季度，Rinvoq 销售额增长了一倍多，达到 4.53 亿美元，超过了分析师平均预期的 4.368 亿美元。</blockquote></p><p> Sales of Skyrizi jumped 83.3% to $796 million, also above estimates of $765 million.</p><p><blockquote>Skyrizi 的销售额增长 83.3%，达到 7.96 亿美元，也高于 7.65 亿美元的预期。</blockquote></p><p> Revenue from Botox, used as an anti-wrinkle injection and for other cosmetic purposes, also beat estimates.</p><p><blockquote>用作抗皱注射和其他美容用途的肉毒杆菌素的收入也超出了预期。</blockquote></p><p> Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion.</p><p><blockquote>艾伯维的总销售额增长 11.2%，达到 143.4 亿美元，略高于预期的 143.2 亿美元。</blockquote></p><p> AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62.</p><p><blockquote>艾伯维目前预计全年调整后每股利润为 12.63 美元至 12.67 美元，而之前的预期为 12.52 美元至 12.62 美元。</blockquote></p><p> Its shares jumped over 1% in premarket trading.<img src=\"https://static.tigerbbs.com/440c6dd8a91b64d48b36982f3b62340e\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过 1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie got a shot in the arm from newer drug sales and lifted profit view<blockquote>艾伯维从新药销售中得到了一剂强心针，利润前景也得到了提升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie got a shot in the arm from newer drug sales and lifted profit view<blockquote>艾伯维从新药销售中得到了一剂强心针，利润前景也得到了提升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-29 19:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.</p><p><blockquote>美国制药商艾伯维公司 (ABBV.N) 周五第三次上调了 2021 年调整后利润预期，此前其新药的出色表现帮助其季度收入超出了华尔街的预期。</blockquote></p><p> The company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition for its blockbuster rheumatoid arthritis drug, Humira.</p><p><blockquote>该公司一直专注于获得更多批准并推动 2019 年推出的 Skyrizi 和 Rinvoq 的增长，为其重磅类风湿性关节炎药物 Humira 的竞争做准备。</blockquote></p><p> Humira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. The company's newer drugs, Skyrizi and Rinvoq, are approved to treat the same conditions as Humira.</p><p><blockquote>修美乐是全球销量最高的药品，占艾伯维总销售额的近40%。该公司的新药Skyrizi和Rinvoq被批准用于治疗与Humira相同的病症。</blockquote></p><p> Humira sales, which rose 5.6% to $5.43 billion in the third quarter, are expected to be squeezed when generic rivals enter the U.S. market in 2023.</p><p><blockquote>修美乐第三季度销售额增长 5.6%，达到 54.3 亿美元，预计当仿制药竞争对手于 2023 年进入美国市场时，销售额将受到挤压。</blockquote></p><p> Rinvoq sales could take a near-term hit, analysts have said, after the U.S. drug regulator asked the company and others to present information about the risks of death and serious conditions from the use of their drugs that belong to a class of treatments known as JAK inhibitors.</p><p><blockquote>分析师表示，Rinvoq 的销售可能会在短期内受到打击，此前美国药品监管机构要求该公司和其他公司提供有关使用属于一类被称为 JAK 抑制剂的药物造成的死亡和严重疾病的风险的信息。</blockquote></p><p> Meanwhile, Rinvoq sales more than doubled to $453 million in the quarter ended Sept. 30, beating the average analyst estimate of $436.8 million, according to Refinitiv IBES estimates.</p><p><blockquote>与此同时，根据 Refinitiv IBES 的估计，截至 9 月 30 日的季度，Rinvoq 销售额增长了一倍多，达到 4.53 亿美元，超过了分析师平均预期的 4.368 亿美元。</blockquote></p><p> Sales of Skyrizi jumped 83.3% to $796 million, also above estimates of $765 million.</p><p><blockquote>Skyrizi 的销售额增长 83.3%，达到 7.96 亿美元，也高于 7.65 亿美元的预期。</blockquote></p><p> Revenue from Botox, used as an anti-wrinkle injection and for other cosmetic purposes, also beat estimates.</p><p><blockquote>用作抗皱注射和其他美容用途的肉毒杆菌素的收入也超出了预期。</blockquote></p><p> Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion.</p><p><blockquote>艾伯维的总销售额增长 11.2%，达到 143.4 亿美元，略高于预期的 143.2 亿美元。</blockquote></p><p> AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62.</p><p><blockquote>艾伯维目前预计全年调整后每股利润为 12.63 美元至 12.67 美元，而之前的预期为 12.52 美元至 12.62 美元。</blockquote></p><p> Its shares jumped over 1% in premarket trading.<img src=\"https://static.tigerbbs.com/440c6dd8a91b64d48b36982f3b62340e\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过 1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140565656","content_text":"U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.\nThe company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition for its blockbuster rheumatoid arthritis drug, Humira.\nHumira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. The company's newer drugs, Skyrizi and Rinvoq, are approved to treat the same conditions as Humira.\nHumira sales, which rose 5.6% to $5.43 billion in the third quarter, are expected to be squeezed when generic rivals enter the U.S. market in 2023.\nRinvoq sales could take a near-term hit, analysts have said, after the U.S. drug regulator asked the company and others to present information about the risks of death and serious conditions from the use of their drugs that belong to a class of treatments known as JAK inhibitors.\nMeanwhile, Rinvoq sales more than doubled to $453 million in the quarter ended Sept. 30, beating the average analyst estimate of $436.8 million, according to Refinitiv IBES estimates.\nSales of Skyrizi jumped 83.3% to $796 million, also above estimates of $765 million.\nRevenue from Botox, used as an anti-wrinkle injection and for other cosmetic purposes, also beat estimates.\nTotal sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion.\nAbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62.\nIts shares jumped over 1% in premarket trading.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":3346,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/857350894"}
精彩评论